{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T19:37:05Z","timestamp":1780601825488,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.radonc.2021.11.017","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T10:58:13Z","timestamp":1637837893000},"page":"203-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Postoperative radiotherapy in stage I\u2013III Merkel cell carcinoma"],"prefix":"10.1016","volume":"166","author":[{"given":"Sonja","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Blankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan","family":"Gr\u00fcnhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Jalving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Hamming-Vrieze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas B.","family":"Been","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Tans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.J.","family":"van Akkooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot E.T.","family":"Tesselaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.11.017_b0005","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1016\/j.jid.2021.04.007","article-title":"International Increases in Merkel Cell Carcinoma Incidence Rates between 1997 and 2016","volume":"141","author":"Olsen","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.radonc.2021.11.017_b0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.11.017_b0015","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/bjd.14950","article-title":"Epidemiological trends in Merkel cell carcinoma in southern France: a registry-based study","volume":"176","author":"Fondain","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.radonc.2021.11.017_b0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.radonc.2021.11.017_b0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2016.10.022","article-title":"Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs","volume":"71","author":"Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.11.017_b0030","doi-asserted-by":"crossref","unstructured":"K.L. Harms, M.A. Healy, P. Nghiem, A.J. Sober, T.M. Johnson, C.K. Bichakjian, S.L. Wong, Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System, Annals of surgical oncology 23(11) (2016) 3564-3571.","DOI":"10.1245\/s10434-016-5266-4"},{"key":"10.1016\/j.radonc.2021.11.017_b0035","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/jso.25090","article-title":"Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients","volume":"117","author":"van Veenendaal","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.radonc.2021.11.017_b0040","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.amjsurg.2020.08.013","article-title":"Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study","volume":"221","author":"Bleicher","year":"2021","journal-title":"Am J Surg"},{"key":"10.1016\/j.radonc.2021.11.017_b0045","unstructured":"C.D. Schmults, R.B. Blitzblau, S.B. Aasi, M. Alam, J.S. Andersen, J. Bordeaux, et al., National Comprehensive Cancer Network Guidelines for Merkel Cell Carcinoma, Version 2, 2019, 2019."},{"key":"10.1016\/j.radonc.2021.11.017_b0050","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1245\/s10434-020-09145-7","article-title":"Reduced wide local excision margins are associated with increased risk of relapse and death from Merkel cell carcinoma","volume":"28","author":"Andruska","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2021.11.017_b0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amjsurg.2017.10.045","article-title":"Surgical resection improves median overall survival with marginal improvement in long-term survival when compared with definitive radiotherapy in Merkel cell carcinoma: A propensity score matched analysis of the National Cancer Database","volume":"215","author":"Wright","year":"2018","journal-title":"Am J Surg"},{"key":"10.1016\/j.radonc.2021.11.017_b0060","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/archderm.142.6.693","article-title":"Adjuvant Local Irradiation for Merkel Cell Carcinoma","volume":"142","author":"Lewis","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.radonc.2021.11.017_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw042","article-title":"Adjuvant radiation therapy and chemotherapy in merkel cell carcinoma: Survival analyses of 6908 cases from the national cancer data base","volume":"108","author":"Bhatia","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.11.017_b0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/14737140.2017.1285233","article-title":"Factors influencing radiation treatment recommendations in early-stage Merkel cell carcinoma: a survey of US-based radiation oncologists","volume":"17","author":"Tseng","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.radonc.2021.11.017_b0075","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jss.2021.03.062","article-title":"Survival Benefit of Guideline-Concordant Postoperative Radiation for Local Merkel Cell Carcinoma","volume":"266","author":"Wong","year":"2021","journal-title":"The Journal of surgical research"},{"key":"10.1016\/j.radonc.2021.11.017_b0080","doi-asserted-by":"crossref","first-page":"E828","DOI":"10.1002\/lary.28866","article-title":"Effect of sentinel lymph node biopsy and LVI on Merkel cell carcinoma prognosis and treatment","volume":"131","author":"Harounian","year":"2021","journal-title":"The Laryngoscope"},{"key":"10.1016\/j.radonc.2021.11.017_b0085","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2019.02.015","article-title":"Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis","volume":"134","author":"Petrelli","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.11.017_b0090","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamadermatol.2013.409","article-title":"Effect of radiation therapy on survival in patients with resected Merkel cell carcinoma: a propensity score surveillance, epidemiology, and end results database analysis","volume":"149","author":"Kim","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.radonc.2021.11.017_b0095","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/atm-20-4578","article-title":"Nomogram prediction for the overall survival and cancer-specific survival of patients diagnosed with Merkel cell carcinoma","volume":"9","author":"Yin","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.radonc.2021.11.017_b0100","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.924570","article-title":"Clinical features and prognosis of Merkel cell carcinoma in elderly patients","volume":"26","author":"Xia","year":"2020","journal-title":"Med Sci Monitor"},{"key":"10.1016\/j.radonc.2021.11.017_b0105","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1001\/jama.289.19.2554","article-title":"Composite outcomes in randomized trials - greater precision but with greater uncertainty?","volume":"289","author":"Freemantle","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2021.11.017_b0110","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1001\/jama.289.19.2575","article-title":"Clinical trials\u2014multiple treatments, multiple end points, and multiple lessons","volume":"289","author":"Lauer","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2021.11.017_b0115","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/bmj.330.7491.594","article-title":"Validity of composite end points in clinical trials","volume":"330","author":"Montori","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2021.11.017_b0120","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/aje\/kwt283","article-title":"Invited commentary: composite outcomes as an attempt to escape from selection bias and related paradoxes","volume":"179","author":"Hernan","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.radonc.2021.11.017_b0125","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/0194599820967001","article-title":"Primary treatment selection for clinically node-negative Merkel cell carcinoma of the head and neck","volume":"164","author":"Jacobs","year":"2021","journal-title":"Otolaryngology\u2013Head Neck Surgery"},{"key":"10.1016\/j.radonc.2021.11.017_b0130","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: A preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2021.11.017_b0135","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.11.017_b0140","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.11.017_b0145","doi-asserted-by":"crossref","first-page":"782","DOI":"10.6004\/jnccn.2018.7049","article-title":"Advances in immunotherapy for metastatic merkel cell carcinoma: A clinician's guide","volume":"16","author":"Paulson","year":"2018","journal-title":"J Natl Compreh Cancer Network JNCCN"},{"key":"10.1016\/j.radonc.2021.11.017_b0150","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1634\/theoncologist.2018-0718","article-title":"Recent therapeutic advances and change in treatment paradigm of patients with merkel cell carcinoma","volume":"24","author":"Garcia\u2010Carbonero","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2021.11.017_b0155","unstructured":"EMA, Summary Of Opinion - Initial Authorisation of Avelumab, Committee for Medicinal Products for Human Use (EMA\/CHMP\/426201\/2017) (2017)."},{"key":"10.1016\/j.radonc.2021.11.017_b0160","doi-asserted-by":"crossref","first-page":"e001076","DOI":"10.1136\/jitc-2020-001076","article-title":"Avelumab for advanced Merkel cell carcinoma in the Netherlands; a real-world cohort","volume":"8","author":"Levy","year":"2020","journal-title":"J ImmunoTherapy Cancer"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021090113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021090113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:21:20Z","timestamp":1759123280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814021090113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":32,"alternative-id":["S0167814021090113"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.11.017","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postoperative radiotherapy in stage I\u2013III Merkel cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}